High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial-Reference-Cited by-同舟云学术

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Published:2009-10 Issue:9700 Volume:374 Page:1512-1520
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ferreri Andrés JM,Reni Michele,Foppoli Marco,Martelli Maurizio,Pangalis Gerasimus A,Frezzato Maurizio,Cabras Maria Giuseppina,Fabbri Alberto,Corazzelli Gaetano,Ilariucci Fiorella,Rossi Giuseppe,Soffietti Riccardo,Stelitano Caterina,Vallisa Daniele,Zaja Francesco,Zoppegno Lucía,Aondio Gian Marco,Avvisati Giuseppe,Balzarotti Monica,Brandes Alba A,Fajardo José,Gomez Henry,Guarini Attilio,Pinotti Graziella,Rigacci Luigi,Uhlmann Catrina,Picozzi Piero,Vezzulli Paolo,Ponzoni Maurilio,Zucca Emanuele,Caligaris-Cappio Federico,Cavalli Franco

Publisher

Elsevier BV

Subject

General Medicine

Reference35 articles.

1. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy;Mead;Cancer,2000

2. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials;Ferreri;Ann Oncol,2000

3. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002;Ferreri;J Clin Oncol,2003

4. A multicenter study of treatment of primary CNS lymphoma;Ferreri;Neurology,2002

5. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients;Guha-Thakurta;J Neurooncol,1999

Cited by 570 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Baseline Pan-Immune‑Inflammation Value (PIV) and PILE in Predicting Clinical Outcomes and Therapeutic Response for Primary Central Nervous System Lymphoma;Journal of Inflammation Research;2024-08

2. Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020;Neuro-Oncology;2024-06-25

3. Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS Lymphoma;JCO Oncology Practice;2024-06-25

4. Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance;eJHaem;2024-06-21

5. Development of a novel nomogram for predicting delayed methotrexate excretion following high-dose methotrexate in adult patients with hematologic malignancies;Cancer Chemotherapy and Pharmacology;2024-06-21